Advertisement

Alnylam Pharmaceuticals Inc. has pulled in a $10 million tech transfer payment from Japanese drug maker Takeda Pharmaceutical Co. Ltd., related to a May 2008 deal between the two companies potentially worth up to $1 billion.

The Cambridge-based RNAi-focused therapeutics firm has now received $150 million from Takeda, between upfront and tech transfer payments stemming from Alnylam’s documents, materials and knowledge platform pertaining to its RNA-interference drugs. Further milestone payments may also be due if Takeda moves the RNAi products along in development.

SOURCE

Advertisement
Advertisement